LinkGevity wins investment from the KQ Labs Program

London, UK-based LinkGevity today announced it has been selected for the prestigious KQ Labs Program, delivered by the Francis Crick Institute, Europe’s largest biomedical research center.

LinkGevity, which is an AI-driven drug discovery company focused on age-related diseases and longevity, explained the KQ Labs Program provides participants with an equity investment, and access to an advanced global scientific network. Only 10 start-ups are chosen annually, after a rigorous due diligence process, for this highly selective initiative that is aimed at propelling world class healthcare innovations forward. LinkGevity’s therapeutic data, innovative approach and scientific leadership secured its place in this elite cohort.

The company’s flagship therapeutic is a first-in-class anti-necrotic, which targets one such pathological pathway - necrosis. It has earned a prestigious Horizon Europe grant from the European Union alongside UK government funding. LinkGevity was also selected as one of only 12 companies globally for the NASA/Microsoft Space-Health Program, due to the anti-necrotic’s potential in preventing accelerated aging and tissue degeneration in astronauts.